COMMUNIQUÉS West-GlobeNewswire

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
26/02/2024
Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant [...]
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
26/02/2024
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of treatment versus [...]
IBA Notice of Full Year 2023 Results and Conference Call
26/02/2024
FY23 results meeting to take place as a hybrid event on Thursday, 21 March 2024 at 3pm CET Louvain-la-Neuve, Belgium, 26 February 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle [...]
IBA : Publication des résultats annuels 2023 et conférence web
26/02/2024
La conférence sur les résultats annuels aura lieu le jeudi 21 mars 2024 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 26 février 2024 - IBA (Ion Beam Applications S.A.), le premier fournisseur mondial de [...]
argenx to Present at Upcoming Investor Conferences
26/02/2024
February 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
25/02/2024
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic [...]
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
24/02/2024
- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups - - Sustained activity with rapid onset within 2 weeks [...]
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
24/02/2024
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed rilzabrutinib, an [...]
Communiqué : Résultats de phase II montrent que le rilzabrutinib permet de réduire rapidement la sévérité des démangeaisons causées par l’urticaire chronique spontanée et d’améliorer significativement l’activité de la maladie chez l’adulte
24/02/2024
Des résultats de phase II montrent que le rilzabrutinib permet de réduire rapidement la sévérité des démangeaisons causées par l’urticaire chronique spontanée et d’améliorer significativement l’activité de la maladie [...]
Tilray Medical salue le Bundestag allemand et l’adoption historique de la loi sur le cannabis à usage médicinal en Allemagne
24/02/2024
La nouvelle loi allemande sur le cannabis à usage médicinal (Medizinal-Cannabisgesetz – « MedCanG ») permet aux patients d’accéder plus facilement à ce produit COLOGNE, Allemagne et NEUMÜNSTER, Allemagne, 24 févr. 2024 [...]
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
24/02/2024
SIMLANDI is t he first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S . SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and [...]
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
24/02/2024
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
23/02/2024
Company Announcement COPENHAGEN, Denmark; February 23, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
23/02/2024
Company Announcement COPENHAGEN, Denmark; February 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and employees of the [...]
Coherus BioSciences Announces New Employment Inducement Grants
23/02/2024
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation committee of the Company’s [...]
NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23/02/2024
EDEN PRAIRIE, Minn., Feb. 23, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and [...]
Celularity Announces 1-for-10 Reverse Stock Split
23/02/2024
FLORHAM PARK, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Celularity, Inc. (Nasdaq: CELU; CELUW) (“Celularity”), a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23/02/2024
NOVATO, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23/02/2024
MALVERN, Pa., Feb. 23, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that [...]

Pages